Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Successful outcomes with rituximab therapy for refractory childhood systemic lupus erythematosus.

Literature DB >> 16508774

Successful outcomes with rituximab therapy for refractory childhood systemic lupus erythematosus.

Stephen D Marks, Kjell Tullus.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2006 PMID： 16508774 DOI： 10.1007/s00467-006-0024-7

Source DB: PubMed Journal: Pediatr Nephrol ISSN： 0931-041X Impact factor: 3.714

× No keyword cloud information.

5 in total

1. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus.

Authors: Stephen D Marks; Sue Patey; Paul A Brogan; Nathan Hasson; Clarissa Pilkington; Patricia Woo; Kjell Tullus
Journal: Arthritis Rheum Date: 2005-10

2. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

Authors: M J Leandro; G Cambridge; J C Edwards; M R Ehrenstein; D A Isenberg
Journal: Rheumatology (Oxford) Date: 2005-09-27 Impact factor: 7.580

3. Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report.

Authors: Monika Edelbauer; Therese Jungraithmayr; Lothar Bernd Zimmerhackl
Journal: Pediatr Nephrol Date: 2005-03-17 Impact factor: 3.714

4. An open study of B lymphocyte depletion in systemic lupus erythematosus.

Authors: Maria J Leandro; Jonathan C Edwards; Geraldine Cambridge; Michael R Ehrenstein; David A Isenberg
Journal: Arthritis Rheum Date: 2002-10

5. Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy.

Authors: R Weide; J Heymanns; A Pandorf; H Köppler
Journal: Lupus Date: 2003 Impact factor: 2.911

5 in total

8 in total

Review 1. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors: D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal: Ann Rheum Dis Date: 2007-11 Impact factor: 19.103

2. Rituximab therapy for steroid-dependent minimal change nephrotic syndrome.

Authors: Rodney D Gilbert; Eleanor Hulse; Susan Rigden
Journal: Pediatr Nephrol Date: 2006-08-24 Impact factor: 3.714

3. Safety and efficacy of rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece.

Authors: Maria Trachana; Artemis Koutsonikoli; Evagelia Farmaki; Nikoleta Printza; Vasiliki Tzimouli; Fotios Papachristou
Journal: Rheumatol Int Date: 2011-11-19 Impact factor: 2.631

4. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.

Authors: Maya H Buch; Josef S Smolen; Neil Betteridge; Ferdinand C Breedveld; Gerd Burmester; Thomas Dörner; Gianfranco Ferraccioli; Jacques-Eric Gottenberg; John Isaacs; Tore K Kvien; Xavier Mariette; Emilio Martin-Mola; Karel Pavelka; Paul P Tak; Desiree van der Heijde; Ronald F van Vollenhoven; Paul Emery
Journal: Ann Rheum Dis Date: 2011-03-06 Impact factor: 19.103